Real-world experience with abiraterone in metastatic castration-resistant prostate cancer

• Main Authors: Yasar Ahmed, Nemer Osman, Rizwan Sheikh, Sarah Picardo, Geoffrey Watson
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2017-01-01
• Series: Cancer Translational Medicine
• Subjects: Abiraterone; castrate resistant; metastatic prostate cancer
• Online Access: http://www.cancertm.com/article.asp?issn=2395-3977;year=2017;volume=3;issue=4;spage=133;epage=138;aulast=Ahmed
• ISSN: 2395-3977; 2395-3012

Aim: To evaluate abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: This is a multicenter retrospective analysis, involving 44 consecutive abiraterone-treated mCRPC patients, in either chemotherapy-naive or postdocetaxel setting. Results: The study cohort's median age was 68.7 (50–88) years, and the median duration of abiraterone treatment was 8 (1–36) months. Of the 44 patients, 23 (52%) and 21 (47%) patients were in chemotherapy- naive and postdocetaxel groups, respectively. Eastern Cooperative Oncology Group performance status score was 0–1 and 2–3 in 65% and 34% of chemotherapy-naive and 85% and 15% of postdocetaxel patients, respectively. Prostate-specific antigen (PSA) response was achieved in 13 (56.5%) chemotherapy-naive and 14 (66.6%) postdocetaxel patients. The median time to PSA progression was 12 (10.5–13.5) months. Objective radiological response was achieved in 11 (34.6%) patients, stable disease in 16 (55.1%) patients, and progressive disease in 3 (6.8%) patients. Median time to radiographic progression was 10.8 (10.3–11.4) months. Median overall survival was not reached (mean = 17 [14–20.5] months). The most common adverse events related to mineralocorticoid excess include hypokalemia (12%), fluid retention/edema (28%), and hypertension (8%). Conclusion: This study supports the safety and efficacy of abiraterone for mCRPC patients in the real-world setting.